ライフサイエンスコーパス: stomatitis

1 en dexamethasone mouthwash for prevention of stomatitis).

2 mar-plantar erythrodysesthesia syndrome, and stomatitis.

3 s are critical for the prevention of denture stomatitis.

4 d the percentage of patients without denture stomatitis.

5 on (55 [19%] of 283 vs 74 [27%] of 271), and stomatitis (138 [49%] of 284 vs 162 [59%] of 273); 60 (2

6 tinib group), rash (29 [7%] vs 12 [3%]), and stomatitis (15 [3%] vs two [<1%]).

7 (54%), anemia (35%), thrombocytopenia (33%), stomatitis (15%), febrile neutropenia (13%), and fatigue

8 manifestations were bloating (20%), aphthous stomatitis (18%), alternating bowel habit (15%), constip

9 e group), diarrhoea (30 [9%] vs three [2%]), stomatitis (20 [6%] vs 13 [8%]), fatigue (18 [6%] vs fiv

10 mus group vs two [5%] in the placebo group), stomatitis (24 [31%] vs eight [21%]), convulsion (18 [23

11 association with everolimus monotherapy were stomatitis (26 [62%] of 42) and diarrhoea (16 [38%]); an

12 in alone group (four [1%]), as was grade 3-4 stomatitis (26 [8%] vs seven [2%]).

13 t common adverse events with everolimus were stomatitis (314 [67%] of 472 patients in the everolimus

14 febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%

15 (39.3%) in the patupilone arm and mucositis/stomatitis (43%) and hand-foot syndrome (41.8%) in the P

16 ion (50.9%), decreased appetite (45.6%), and stomatitis (45.6%).

17 Stomatitis (48 [43%] patients) and mouth ulceration (33

18 ts in the everolimus and placebo groups were stomatitis (48% [38 of 79], 8% [3 of 39], respectively),

19 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%] vs 10 [3%]), hypokalaemia (52 [15%]

20 re fatigue (72% v 53% with tamoxifen alone), stomatitis (56% v 7%), rash (44% v 7%), anorexia (43% v

21 up were neutropenia (117 [25%] vs 35 [15%]), stomatitis (59 [13%] vs three [1%]), anaemia (46 [10%] v

22 most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group v

23 vely), fatigue (11.1% v 4.2%, respectively), stomatitis (8.8% v 0.7%, respectively), and hypertension

24 o p63 are associated with chronic ulcerative stomatitis, an oral immunologically mediated disease.

25 limiting toxic effects-one developed grade 3 stomatitis and fatigue and one developed arthralgia and

26 antiviral effects of IFN1 against vesicular stomatitis and hepatitis C viruses in human cells and pr

27 a and Lassa fever VLPs, as well as vesicular stomatitis and rabies viruses (VSV and RABV, respectivel

28 of periodontal diseases, recurrent aphthous stomatitis, and candidiasis.

29 ent drug-related toxicities included nausea, stomatitis (both 53%), and anemia (48%).

30 ger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting.

31 y endpoint was incidence of grade 2 or worse stomatitis by 8 weeks assessed in the full analysis set

32 influenza A, Zika, Ebola, Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not murine leukemi

33 he incidences of grade 3 or 4 neurotoxicity, stomatitis, diarrhea, and neutropenia were significantly

34 Denture stomatitis (DS) is a fungal infection characterized by i

35 adverse event reported was grade 3 or worse stomatitis during both induction (87 of 242 patients in

36 hyperglycaemia (seven [17%] of 42 patients), stomatitis (four [10%]), and diarrhoea (three [7%]); tho

37 limus/bevacizumab were mucosal inflammation, stomatitis, hypophosphatemia, hyperglycemia, and hyperch

38 patients, dry skin in 39 (44%) patients, and stomatitis in 36 (40%) patients.

39 1%] vs three [1.1%] and methotrexate-related stomatitis in 48 [18.0%] vs 12 [4.5%]).

40 tially reduced the incidence and severity of stomatitis in patients receiving everolimus and exemesta

41 amethasone-based mouthwash for prevention of stomatitis in patients with breast cancer.

42 adverse events were infrequent and included stomatitis (in 18 [9%] of 202 patients in the everolimus

43 Topical steroids might reduce stomatitis incidence and severity, and the need for dose

44 te systems such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses or gammaret

45 AEs) more common with ridaforolimus included stomatitis, infections, fatigue, thrombocytopenia, nonin

46 Stomatitis is a class effect associated with the inhibit

47 Denture-associated stomatitis is a common candidal infection that may give

48 tudied the cytotoxic activity of a vesicular stomatitis/measles hybrid virus (VSV-FH), which is super

49 mild or moderate and consisted primarily of stomatitis, mucosal inflammation, mouth ulceration, rash

50 s receiving EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fat

51 uded gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4).

52 dverse events, the most common of which were stomatitis (nine [8%]) and pneumonia (nine [8%]).

53 one [2%]), pneumonitis (none vs five [9%]), stomatitis (none vs five [9%]), and hand-foot syndrome (

54 ) were upper respiratory tract infection and stomatitis of mostly grade 1 or 2 severity.

55 aronychia (26 [11%] in LUX-Lung 3 only), and stomatitis or mucositis (13 [5%] in LUX-Lung 6 only).

56 of 239 patients), diarrhoea (13 [5.4%]), and stomatitis or mucositis (13 [5.4%]), compared with neutr

57 OR=1.54, P=0.001), and no detectable denture stomatitis (OR=2.89, P<0.001) significantly increased af

58 rmalities than placebo (especially diarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome,

59 arm had a significantly higher incidence of stomatitis (P < .001), hand-foot syndrome (P < .001), an

60 human cells and proved beneficial in feline stomatitis patients.

61 Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) i

62 pediatric disorder periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndr

63 to infection by Lassa, measles and vesicular stomatitis pseudoviruses.

64 tandem repeat polymorphism was predictive of stomatitis (R(2) = 0.018; P = .009), a frequent side eff

65 udotyped with different envelopes (vesicular stomatitis, Rabies, Mokola and Ross River viral envelope

66 Recurrent aphthous stomatitis (RAS) is the most common disease affecting or

67 the use of ozone to treat recurrent aphthous stomatitis (RAS).

68 The most common adverse events included stomatitis, rash, and diarrhea.

69 sient detection of the recombinant vesicular stomatitis vaccine virus in blood.

70 EPNs that incorporate the vesicular stomatitis viral glycoprotein can fuse with target cells

71 , we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV capsid prot

72 icensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycopr

73 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolaviru

74 clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated th

75 fter immunization with recombinant vesicular stomatitis virus (rVSV) vaccine vectors, and if so, to i

76 Recombinant vesicular stomatitis virus (rVSV) was shown to be a highly effecti

77 ing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccine vectors

78 replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed

79 replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire

80 is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEB

81 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which enc

82 plicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surface glycop

83 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic ductal adenoca

84 ediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (CHAV), whic

85 s simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) and impaired the replication of b

86 functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis

87 ive template for RNA synthesis for vesicular stomatitis virus (VSV) and other negative-strand viruses

88 protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catalyzes the t

89 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdoviruses (e.g.,

90 ns with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncytial Virus (

91 NA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV), are com

92 e experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus (TEV), we

93 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as anticance

94 have been employed here to purify vesicular stomatitis virus (VSV) as a model case, however this tec

95 specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-IRIS platf

96 Using vesicular stomatitis virus (VSV) as a model, we coinfected BHK cel

97 ribe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeric hemagglu

98 nstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) assemble to include CD46 and CD55

99 Vesicular stomatitis virus (VSV) assembly requires condensation of

100 can be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glycoprotein.

101 Recombinant vesicular stomatitis virus (VSV) encoding the hemagglutinin-like e

102 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F and H entry

103 with systemic administration of a vesicular stomatitis virus (VSV) engineered to express the endogen

104 Vesicular stomatitis virus (VSV) exhibits a remarkably robust and

105 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycopr

106 cine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envel

107 Moloney murine leukemia virus and vesicular stomatitis virus (VSV) G glycoproteins; and (iii) a loss

108 ral particles pseudotyped with the vesicular stomatitis virus (VSV) G protein with dextran-supported

109 ng protein 2 (PCBP2) downregulates vesicular stomatitis virus (VSV) gene expression.

110 ring RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth.

111 Vesicular stomatitis virus (VSV) has been extensively studied as a

112 Replication of vesicular stomatitis virus (VSV) has long served as a model for un

113 its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a systemic oncolyt

114 Vesicular stomatitis virus (VSV) has shown considerable promise bo

115 Vesicular stomatitis virus (VSV) has shown substantial promise, bu

116 tonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprotein was rep

117 compassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L protein with t

118 78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresponding enh

119 ating the host IFN response during vesicular stomatitis virus (VSV) infection.

120 as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

121 Vesicular stomatitis virus (VSV) is a highly cytopathic virus bein

122 Vesicular stomatitis virus (VSV) is a promising oncolytic agent ag

123 Vesicular stomatitis virus (VSV) is a promising oncolytic agent ag

124 Vesicular stomatitis virus (VSV) is a promising oncolytic virus (O

125 Recombinant vesicular stomatitis virus (VSV) is a promising therapeutic vaccin

126 Vesicular stomatitis virus (VSV) is potent and a highly promising

127 Vesicular stomatitis virus (VSV) is the prototype for negative sen

128 ryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

129 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cytoplasm of

130 The vesicular stomatitis virus (VSV) nucleoprotein (N) associates tigh

131 ell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV.

132 Assembly of vesicular stomatitis virus (VSV) particles requires the separate t

133 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid dendritic

134 ree of shielding and the amount of vesicular stomatitis virus (VSV) particles.

135 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and transduction

136 s; loss of Toll-7 led to increased vesicular stomatitis virus (VSV) replication and mortality.

137 y RNAi inhibited an early stage of vesicular stomatitis virus (VSV) replication.

138 The vesicular stomatitis virus (VSV) RNA-dependent RNA polymerase cons

139 genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable promise both a

140 spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cells in a mo

141 udy, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neu

142 developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targets transfo

143 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore and eithe

144 inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that regulate

145 t utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the na

146 accine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and express in

147 Vesicular stomatitis virus (VSV) vectors that express heterologous

148 a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 es

149 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its G glycopro

150 s work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of Maraba vir

151 od is demonstrated on an RNA-based vesicular stomatitis virus (VSV) with oncolytic properties.

152 Vesicular stomatitis virus (VSV), a negative-sense RNA virus, repl

153 Work with vesicular stomatitis virus (VSV), a prototype, supports a model of

154 , but has no appreciable effect on vesicular stomatitis virus (VSV), a rhabdovirus.

155 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer, or natur

156 t MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STING that can

157 pseudotype glycoprotein-deficient vesicular stomatitis virus (VSV), allowing studies of BASV-G-drive

158 rvation, we engineered a strain of vesicular stomatitis virus (VSV), an oncolytic rhabdovirus that bo

159 f these ISGs against an RNA virus, vesicular stomatitis virus (VSV), and a DNA virus, murine gammaher

160 took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothesis that t

161 abies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the codon-opti

162 bdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type or codon-op

163 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rabies virus,

164 on with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

165 tamers against an oncolytic virus, vesicular stomatitis virus (VSV), to protect it from nAbs.

166 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three passages

167 those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that both polymer

168 s and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA complementary to

169 By studying vesicular stomatitis virus (VSV), we identify the large ribosomal

170 Working with vesicular stomatitis virus (VSV), we previously showed that a pane

171 strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinjection of V

172 of a novel viral tracer, based on vesicular stomatitis virus (VSV), which directs retrograde transsy

173 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses that inclu

174 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine candidate

175 Using a vesicular stomatitis virus (VSV)-based pseudoparticle seroneutrali

176 Here, vesicular stomatitis virus (VSV)-based pseudovirions displaying di

177 repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 million, 20 mi

178 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVSV-ZEBOV, a

179 In the vesicular stomatitis virus (VSV)-induced encephalitis model, the r

180 case (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of type I IFN

181 d, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta (IFNbeta)-

182 ls that are resistant to oncolytic vesicular stomatitis virus (VSV).

183 a virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

184 ma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

185 l of prostate cancer infected with vesicular stomatitis virus (VSV).

186 gets for the matrix (M) protein of vesicular stomatitis virus (VSV).

187 uses comes largely from studies of vesicular stomatitis virus (VSV).

188 was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

189 on by the neurotropic rhabdovirus, vesicular stomatitis virus (VSV).

190 ibits the replication of HSV-1 and vesicular stomatitis virus (VSV).

191 c viruses, such as the neurotropic vesicular stomatitis virus (VSV).

192 ed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA virus) to ex

193 which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initiation of f

194 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovirus [CMV])

195 y endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fuse in the

196 Vesicular stomatitis virus and influenza A virus infection increas

197 infection of IL-21R(-/-) mice with vesicular stomatitis virus and influenza virus.

198 to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to transfection wi

199 iral infections with influenza and vesicular stomatitis virus can persist after resolution of infecti

200 endent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-mRNA cappi

201 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sole attachme

202 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona variant GP1

203 glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon (IFN-beta

204 ollowing intranasal infection with vesicular stomatitis virus expressing OVA and influenza B and incr

205 e vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-E

206 asmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycopr

207 s to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycopr

208 fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

209 ion of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-

210 rprisingly, not the trafficking of vesicular stomatitis virus G protein (VSV-G) to the cell surface.

211 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of internalized tr

212 th virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promoted the form

213 of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in

214 havirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the only struct

215 rus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been described

216 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruse

217 nd that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased the amoun

218 ancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with modified gi

219 o retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

220 Vesicular stomatitis virus has been shown to bud basolaterally, an

221 iral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN receptor-depen

222 ous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vector express

223 tion, prolonged protection against vesicular stomatitis virus infection and enhanced transcriptional

224 ly after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cytolytic func

225 Ig in response to immunization or vesicular stomatitis virus infection is strongly impaired.

226 hocytic choriomeningitis virus and vesicular stomatitis virus infection models.

227 otic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble into small a

228 inhibition during influenza A and vesicular stomatitis virus infection, but not murine hepatitis vir

229 Using an intranasal vesicular stomatitis virus infection, we demonstrated that EYFP(+)

230 to induce apoptosis in response to vesicular stomatitis virus infection.

231 for EmGFP/IL-15 upregulation after vesicular stomatitis virus infection.

232 Here, we define that vesicular stomatitis virus L initiates synthesis via a de-novo mec

233 with encephalomyocarditis virus or vesicular stomatitis virus led to higher levels of autophagy in wi

234 n also occurred in the presence of vesicular stomatitis virus M (matrix) protein, another viral inhib

235 nal approach to the attenuation of vesicular stomatitis virus neurovirulence.

236 ults were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola virus glyc

237 Among vaccines, only the vesicular stomatitis virus platform has been successful in providi

238 igen binding fragment (Fab) of antivesicular stomatitis virus polyclonal antibodies to shield the vir

239 pact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

240 Using vesicular stomatitis virus pseudovirions bearing EBOV glycoprotein

241 red by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack native G glycop

242 hows reduced capability to control vesicular stomatitis virus replication and to induce apoptosis in

243 both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

244 interferon production and enhanced vesicular stomatitis virus replication.

245 HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-cell fusion.

246 from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synthesis and

247 nd 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

248 We have used a collection of vesicular stomatitis virus strains that had been evolving either u

249 not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G).

250 (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in Liberia.

251 fficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/304

252 to infection by the nonretrovirus vesicular stomatitis virus were indistinguishable.

253 her RNA viruses (Sindbis virus and vesicular stomatitis virus) are not.

254 TLR3-dependent viruses (HSV-1 and vesicular stomatitis virus) were high in fibroblasts from both pat

255 s involving viral vectors (such as vesicular stomatitis virus), and antisense compounds directly targ

256 rticle, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruses, which h

257 Vesicular stomatitis virus, a single-stranded RNA virus, triggers

258 virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, and measles

259 luding encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susceptible ce

260 the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

261 ruses, including Sindbis virus and vesicular stomatitis virus, but this innate restriction can be ove

262 s, including influenza A virus and vesicular stomatitis virus, by a mechanism independent of IFN and

263 igens are expressed by vaccinia or vesicular stomatitis virus, either as proteasome-liberated precurs

264 irus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus type 1, o

265 n entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis virus, an

266 on of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A virus, and

267 us viruses pseudotyped with HIV-1, vesicular stomatitis virus, or murine leukemia virus Env glycoprot

268 enges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in

269 an UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

270 Remarkably, infection with vesicular stomatitis virus, vaccinia virus, and a variety of influ

271 with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion RNA polym

272 recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a su

273 ing units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the

274 recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glyc

275 n phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycop

276 cells well supported single round vescicular stomatitis virus-G pseudotyped virus replication, wherea

277 ression enhanced rhinovirus 16 and vesicular stomatitis virus-mediated proinflammatory cytokine produ

278 entry or coreceptor expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication was also

279 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-ZEBOV is cu

280 e results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer pro

281 immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein

282 valuated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein

283 beta, in protection from oncolytic vesicular stomatitis virus.

284 6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

285 e from neuropathogenesis caused by vesicular stomatitis virus.

286 tion by Listeria monocytogenes and vesicular stomatitis virus.

287 rom death after CNS infection with vesicular stomatitis virus.

288 G-I and resistance to infection by vesicular stomatitis virus.

289 otypes bearing the glycoprotein of vesicular stomatitis virus.

290 advantage for host defense against vesicular stomatitis virus.

291 ed after intranasal challenge with vesicular stomatitis virus.

292 able to neutralize RPV-pseudotyped vesicular stomatitis virus.

293 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high doses com

294 Here we test replication-competent vesicular stomatitis viruses (VSV) on 19 primary human melanoma sa

295 eplication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenoviruses was als

296 We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of mult

297 y 8 weeks, the incidence of grade 2 or worse stomatitis was two (2%) of 85 patients (95% CI 0.29-8.24

298 e most common were rash, hyperglycaemia, and stomatitis, which each affected two [2%] patients).

299 afatinib (39 [10%] vs nine [2%]), of grade 3 stomatitis with afatinib (16 [4%] vs none), and of grade

300 neutropenia, impaired wound healing, severe stomatitis with oral stenosis, and death.